CA3145530A1 - Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same - Google Patents

Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same Download PDF

Info

Publication number
CA3145530A1
CA3145530A1 CA3145530A CA3145530A CA3145530A1 CA 3145530 A1 CA3145530 A1 CA 3145530A1 CA 3145530 A CA3145530 A CA 3145530A CA 3145530 A CA3145530 A CA 3145530A CA 3145530 A1 CA3145530 A1 CA 3145530A1
Authority
CA
Canada
Prior art keywords
weight
formulation
pharmaceutical formulation
lysozyme
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3145530A
Other languages
English (en)
French (fr)
Inventor
Diogenes AYBAR-BATISTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aybar Ecotechnologies Corp
Original Assignee
Aybar Ecotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aybar Ecotechnologies Corp filed Critical Aybar Ecotechnologies Corp
Publication of CA3145530A1 publication Critical patent/CA3145530A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3145530A 2019-05-28 2020-05-28 Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same Pending CA3145530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853215P 2019-05-28 2019-05-28
US62/853,215 2019-05-28
PCT/IB2020/055083 WO2020240472A1 (en) 2019-05-28 2020-05-28 Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same

Publications (1)

Publication Number Publication Date
CA3145530A1 true CA3145530A1 (en) 2020-12-03

Family

ID=73551002

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3145530A Pending CA3145530A1 (en) 2019-05-28 2020-05-28 Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same

Country Status (12)

Country Link
US (3) US20200376094A1 (enExample)
EP (1) EP3976093A4 (enExample)
JP (3) JP7768769B2 (enExample)
CN (1) CN114126643A (enExample)
AR (1) AR119031A1 (enExample)
BR (1) BR112021024001A2 (enExample)
CA (1) CA3145530A1 (enExample)
CO (1) CO2021017958A2 (enExample)
IL (1) IL288531A (enExample)
MX (1) MX2021014634A (enExample)
TW (1) TW202110474A (enExample)
WO (1) WO2020240472A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112805027B (zh) * 2020-04-27 2023-10-10 广州新创忆药物临床研究有限公司 一种抗新冠病毒感染的药物与应用
WO2021217702A1 (zh) * 2020-04-27 2021-11-04 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用
WO2023133412A2 (en) * 2022-01-05 2023-07-13 Prophase Labs, Inc. Compositions having synergistic anti-viral action and methods for treating coronavirus
CN114503981A (zh) * 2022-01-07 2022-05-17 上海膜益信息科技有限公司 一种不分层防霉液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK501686A (da) * 1986-10-20 1988-04-21 Otto Melchior Poulsen Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
CN1557485A (zh) * 2004-01-30 2004-12-29 大连帝恩生物工程有限公司 基因重组人溶菌酶在消除病原微生物感染炎症上的应用
PT1755576E (pt) * 2004-04-08 2011-10-19 Dermcare Vet Pty Ltd Composições antimicrobianas e métodos para a sua utilização
CN1583170A (zh) * 2004-06-10 2005-02-23 安米 用于抗病毒抗耐药菌的人溶菌酶药物及其制法
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
US8097434B2 (en) * 2007-10-19 2012-01-17 Becton, Dickinson And Company Methods for the detection of beta-lactamases
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
UA48016U (ru) * 2010-01-25 2010-02-25 Илона Васильевна Ковач Способ профилактики кариеса зубов у детей 3-6 лет
UA68612U (ru) * 2012-02-07 2012-03-26 Дмитрий Викторович Дудар Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией
CN111973484A (zh) * 2013-03-12 2020-11-24 普莱玛疗法公司 包含螯合剂和碱的牙用组合物
JP7055814B2 (ja) * 2017-02-28 2022-04-18 プリシジョンバイオティクス・グループ・リミテッド 呼吸器ウイルス感染症に対する免疫応答を有利に調節することができるビフィドバクテリウム・ロンガム
US20200215169A1 (en) * 2017-07-17 2020-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antibacterial methods and related kits
CN107899006A (zh) * 2017-11-28 2018-04-13 四川清舒乐科技有限公司 冲洗鼻腔的药物组合物及其制备方法

Also Published As

Publication number Publication date
CN114126643A (zh) 2022-03-01
US20200376094A1 (en) 2020-12-03
TW202110474A (zh) 2021-03-16
BR112021024001A2 (pt) 2022-01-25
WO2020240472A1 (en) 2020-12-03
CO2021017958A2 (es) 2022-01-17
EP3976093A4 (en) 2023-07-05
AR119031A1 (es) 2021-11-17
US20240066105A1 (en) 2024-02-29
EP3976093A1 (en) 2022-04-06
JP2026021451A (ja) 2026-02-10
JP2025038034A (ja) 2025-03-18
IL288531A (en) 2022-01-01
JP7768769B2 (ja) 2025-11-12
MX2021014634A (es) 2022-07-04
US20220362354A1 (en) 2022-11-17
JP2022534776A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
US20240066105A1 (en) Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same
US9925206B2 (en) Compositions and methods for treating bacterial infection
US20200352986A1 (en) Methods and compositions for alleviating respiratory dysfunction
JP2010511039A5 (enExample)
JP2016517875A (ja) 抗菌性組成物およびその生成法
US9913801B2 (en) Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione
HUP0002125A2 (hu) Tökéletesített retard hatású mikróbaellenes szerek
Wang Roles of oral bacteria in cardiovascular diseases—from molecular mechanisms to clinical cases: treatment of periodontal disease regarded as biofilm infection: systemic administration of azithromycin
Zou et al. The first case of teeth discoloration induced by linezolid in children in China Mainland
Nickles et al. Evaluation of two siblings with Papillon‐Lefèvre syndrome 5 years after treatment of periodontitis in primary and mixed dentition
Solomon et al. An efficacious oral health care protocol for immunocompromised patients
US20030073625A1 (en) Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides
RU2810419C1 (ru) Способ лечения хронического пародонтита
Al-Sharifi et al. Efficacy of citric acid on periodontal disease.
Baykulova et al. Oral hygiene for severe care: a literature review
RU2214217C1 (ru) Способ лечения пародонтита
Badiea Efficacy of Intra-Pocket Application of Two Antimicrobial Agents as an Adjunct to Mechanotherapy of Chronic Periodontitis (a Comparative Study)
Wilson et al. Comparison of the Effectiveness of Oral and Intravenous Antibiotics for the Treatment of Acute Sinusitis in Children at Skopje Hospital, Macedonia
EA052469B1 (ru) Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов
US9408883B2 (en) Essential oil of Kunzea ambigua and methods of use
JP2024507417A (ja) イヌパルボウイルス感染を治療するための組成物および方法
Swami et al. Role of Azithromycin in Periodontal Diseases.
US20110256246A1 (en) Essential oil of kunzea ambigua and methods of use
Mahmood Evaluation of the effectiveness of coenzyme Q10 gel in management of patients with chronic periodontitis (I intra group comparison)
US20100129475A1 (en) Essential oil of kunzea ambigua and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240129

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - SMALL

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250528

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250704

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251230

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251230